Investment highlights
Raising a $1.5M seed to complete trials, regulatory prep, and early commercialization
Arcus Medical is advancing a minimally invasive approach to pelvic organ prolapse care. The seed round funds the path through clinical validation, FDA regulatory preparation, and early commercial readiness.
Why Arcus
A focused, capital-efficient opportunity
Protected IP
Patented TLT technology — U.S. filings granted, Europe and China pending.
Capital-efficient
The seed funds trials, regulatory prep, and early commercialization.
Clear exit path
Strategic acquisition targets across women's health and medtech portfolios.
Use of proceeds
Where the seed round goes
01
Clinical validation
Advancing testing to support performance and safety of the TLT approach.
02
Regulatory preparation
Building the documentation and process toward FDA review.
03
Early commercialization
Laying the groundwork for an office- and ASC-based go-to-market.
Investor relations
Request the investor materials
Schedule a conversation to review clinical progress, the data room, and the current financing round.